ID: ALA3398482

Max Phase: Preclinical

Molecular Formula: C21H20FN7O

Molecular Weight: 405.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCN(CCn1ccc(-c2ccc(F)cn2)n1)C(=O)c1ccccc1-n1nccn1

Standard InChI:  InChI=1S/C21H20FN7O/c1-2-27(21(30)17-5-3-4-6-20(17)29-24-10-11-25-29)13-14-28-12-9-19(26-28)18-8-7-16(22)15-23-18/h3-12,15H,2,13-14H2,1H3

Standard InChI Key:  WNLPXECFJHLAQT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 405.44

Molecular Weight (Monoisotopic): 405.1713

AlogP: 2.83

#Rotatable Bonds: 7

Polar Surface Area: 81.73

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.57

CX LogP: 2.14

CX LogD: 2.14

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.47

Np Likeness Score: -2.02

References

1. Suzuki R, Nozawa D, Futamura A, Nishikawa-Shimono R, Abe M, Hattori N, Ohta H, Araki Y, Kambe D, Ohmichi M, Tokura S, Aoki T, Ohtake N, Kawamoto H..  (2015)  Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist.,  23  (6): [PMID:25693785] [10.1016/j.bmc.2015.01.044]

2. Boss C, Roch C..  (2015)  Recent trends in orexin research--2010 to 2015.,  25  (15): [PMID:26045032] [10.1016/j.bmcl.2015.05.012]

3. Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, Tokumaru Y, Kirinuki S, Hiyoshi T, Aoki T, Kambe D, Nozawa D..  (2020)  Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia.,  28  (13): [PMID:32482533] [10.1016/j.bmc.2020.115489]

Source

Source(1):

• Scientific Literature